Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for DTX301 in Ornithine transcarbmylase deficiency. The expected timing is based on the latest available company guidance and may change.
Enh3ance study. 8/22/23- Trial ongoing. 2/13/25- Enrollment completed. 11/04/25:- PR No update. 01/12/26:- PR No update. 03/12/26:- Enh3ance Ph3 Week36 met primary endpoint; 64-week follow-up data expected H1 2027. 05/05/26:- Detailed Week36 Ph3 data show significant ammonia reduction and symptom improvement; 64-week follow-up data still expected H1 2027. 08/04/26:- Enh3ance Ph3 64-week treatment-burden endpoint data expected H1 2027.
Verification
Confirm timing and program details against the company announcement or filing.